RxDoctor Payments Data

Joanna Kolodney, MD

Hematology & Oncology · Morgantown, WVNPI 1073704466

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,200 of the $3,171 with a category attached, or 69.4%. Bayer accounts for 73.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,342 and has fallen 76.9% since, to $541 in 2025.

$3,171in general payments, 2019–2025

Across 13 payments — averaging $243.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • E.r. Squibb & Sons, L.L.C.$264
  • Exelixis Inc.$175
  • Immunocore Limited$122
  • Sumitomo Pharma America, Inc.$116
  • AVEO Pharmaceuticals, Inc.$100
  • plus $52 from 2 others
$653,612in research payments, 2019–2025

Across 164 payments — averaging $3985.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$352K
  • Takeda Pharmaceuticals U.S.A., Inc.$169K
  • Genentech, Inc.$119K
  • Novocure Inc.$13K
  • Incyte Corporation$1K

What the payments were for

  • Consulting fees$2,20069%
  • Food & beverage$83126%
  • Education$1414%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,171 in reported general payments places this provider in the 70th percentile of 72 hematology & oncology providers in West Virginia.

See all hematology & oncology providers in West Virginia

Medicare billing

Part B allowed, 2024
$53,881
Medicare patients
171
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide15$199,966
LonsurfTrifluridine/Tipiracil Hcl11$171,104
BraftoviEncorafenib11$152,956
Abiraterone Acetate45$127,132
XtandiEnzalutamide11$119,995
OrgovyxRelugolix12$33,478
Ondansetron Hcl42$282
Dexamethasone26$236
Prednisone52$217
Prochlorperazine Maleate18$202
Levothyroxine Sodium26$185
Lidocaine-PrilocaineLidocaine/Prilocaine11$116
Pantoprazole Sodium14$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$2,342$199,96615 claims
Sumitomo Pharma America, Inc.Orgovyx$116$33,47812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 72 hematology & oncology providers in West Virginia.

Other hematology & oncology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →